May 23, 2022
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating a new side-effect risk for Opdivo (nivolumab) and Keytruda (pembrolizumab), PD-1 inhibitors marketed by Ono Pharmaceutical and MSD, a move likely to trigger label changes in the near future. According to...read more